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Background
Huntington's disease (HD) is an autosomal dominant
neurodegenerative disorder, which occurs in patients with
a mutation in the IT15 gene (huntingtin). Clinically, the
disease presents itself with not only motor symptoms but
also dementia. The aim of this study is to review and
present all recent data, specifically those related to the
neuropathology, biochemistry and diagnostic methods of
dementia in HD.
Materials and methods
Recent advances in molecular and genetic research of HD,
derived from articles published in journals indexed in
PubMed and other Entrez medical databases are being
reviewed in an effort to elucidate mechanisms of cell
death in the striatum and disruption of cortical-striatal cir-
cuitry. Neurophysiological and imaging diagnostic meth-
ods are analytically described, while the utility of other
rating scales, like the Unified HD Rating Scale, in the dif-
ferential diagnosis between HD and other dementias is
evaluated according to several clinical trials, described in
various biomedical literature citations.
Results
HD causes widespread CNS changes and systemic abnor-
malities, while cell death mechanisms involve variable
processes, such as mitochondrial abnormalities, excito-
toxicity, neuroinflammation and abnormal protein degra-
dation [1]. Genetic testing, consideration of the inherited
disease risk, clinical assessment, neuroimaging tech-
niques, cognitive and psychological rating scales contrib-
ute significantly not only to HD diagnosis, but also
prognosis [2].
Conclusions
HD is a devastating neurological condition of long dura-
tion. Many factors likely contribute to neuron death and
dysfunction, making the systematic address of its pathol-
ogy difficult. The first signs and symptoms are often
present before impairments reach a point where the neu-
rologic disease manifests itself, but usually are subtle and
remain unnoticed [3,4]. For this reason, clinical rating
should focus not only on motor difficulties, but also on
the neuropsychological performance of patients as a
whole, aiming to detect different types of impairment
within this neuropsychiatric disorder. Further research in
relation to the understanding of the mechanisms involved
in the memory and cognitive impairment of HD and
enrichment of the diagnostic tools of all cognitive and
emotional declines early in the disease process can have
implications for prognostic assessment of persons at risk
and eventually assist with early interventions.
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